Cooley advised Scancell, a late-stage clinical biotechnology company, on its agreement to acquire Neuphoria Therapeutics, a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders.
In connection with the transaction, Cooley also advised Scancell on a concurrent private financing of $89 million through a combination of equity and debt.
Scancell to Acquire Neuphoria, Concurrent $89 Million Private Financing